Healthcare Industry News: embolic protection
News Release - February 8, 2008
ev3 Inc. Accepts Resignation of Dr. John Simpson
PLYMOUTH, Minn., Feb. 8 (HSMN NewsFeed) -- ev3 Inc. (Nasdaq: EVVV ), a global endovascular device company, today announced the resignation of Dr. John Simpson from his position as Chief Scientist and from the company's board of directors effective February 7, 2008."Over the last thirty years, few people have shaped the treatment of cardiovascular disease as much as Dr. John Simpson with his numerous inventions and vision for improving the lives of patients worldwide," said Jim Corbett, chairman, president and chief executive officer of ev3 Inc. "He leaves a legacy of innovation and a foundation on which we intend to build in our effort to improve patient treatment."
With the resignation of Dr. Simpson, the ev3 board of directors has nine members, of which six are independent directors.
About ev3 Inc.
Since its founding in 2000, ev3 has been dedicated to improving the lives of patients with vascular disease through the development of innovative endovascular therapies. ev3's products are used by endovascular specialists to treat a wide range of peripheral vascular and neurovascular diseases and disorders. The company offers a comprehensive portfolio of treatment options, including the primary interventional technologies used today - peripheral angioplasty balloons, stents, plaque excision systems, embolic protection devices, liquid embolics, embolic coils, thrombectomy catheters and occlusion balloons. More information about the company and its products can be found at http://www.ev3.net.
ev3, the ev3 logo and FoxHollow are trademarks of ev3 Inc., registered in the U.S. and other countries. All trademarks and trade names referred to in this press release are the property of their respective owners.
Source: ev3
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
